ArticleScientific reports2026
Huperzine A improves neurological function in mice with intracerebral hemorrhage by alleviating neuroinflammation and ferroptosis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Intracerebral hemorrhage (ICH) is a devastating neurological condition that is characterized by high morbidity and long-term disability, which frequently results in severe neurological deficits. Given the limited therapeutic options, pharmacological neuroprotection has emerged as a crucial area of research. This study explored the neuroprotective potential of huperzine A (HupA) in a murine model of collagenase-induced ICH in the caudate nucleus. Three experimental groups-Sham, ICH, and ICH + HupA-were assessed at multiple timepoints (1, 3, 7, and 14 days post-ICH) for neurological function, neuroinflammatory responses, and ferroptosis-related markers. Our findings reveal that HupA exerts significant neuroprotection through dual mechanisms: (1) attenuating neuroinflammation via the suppression of IL-1β/IL-6 release and inhibition of glial activation, and (2) mitigating ferroptosis by reducing iron accumulation and upregulating glutathione peroxidase 4 (GPX4) expression, and thereby preserving neuronal viability. These results highlight the therapeutic potential of HupA in alleviating ICH-induced brain injury, and thereby offers a promising multi-target strategy for ICH treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.